Alerts will be sent to your verified email
Verify EmailQLINE
|
Q-Line Biotech
|
Poly Medicure
|
Tarsons Products
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
n/a | 1.47 % | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
20.43 % | 14.36 % | 15.11 % |
|
5yr average Equity Multiplier
|
2.15 | 1.28 | 1.58 |
|
5yr Average Asset Turnover Ratio
|
0.67 | 0.64 | 0.42 |
|
5yr Avg Net Profit Margin
|
14.48 % | 17.65 % | 21.38 % |
|
Price to Book
|
n/a | 4.7 | 1.85 |
|
P/E
|
n/a | 45.3 | 81.92 |
|
5yr Avg Cash Conversion Cycle
|
33.2 Days | 48.25 Days | 148.95 Days |
|
Inventory Days
|
111.38 Days | 57.3 Days | 100.31 Days |
|
Days Receivable
|
63.42 Days | 67.43 Days | 73.25 Days |
|
Days Payable
|
167.28 Days | 95.26 Days | 48.6 Days |
|
5yr Average Interest Coverage Ratio
|
6.19 | 26.49 | 19.57 |
|
5yr Avg ROCE
|
23.27 % | 18.85 % | 16.36 % |
|
5yr Avg Operating Profit Margin
|
20.3 % | 25.65 % | 39.46 % |
|
5 yr average Debt to Equity
|
0.69 | 0.11 | 0.28 |
|
5yr CAGR Net Profit
|
-2.61 % | 20.03 % | -15.44 % |
|
5yr Average Return on Assets
|
9.72 % | 11.2 % | 9.89 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
n/a | 62.42 % | 47.3 % |
|
Share Pledged by Promoters
|
n/a | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
n/a | 9.11 % | -0.01 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
n/a | 5.82 % | -7.64 % |
|
Q-Line Biotech
|
Poly Medicure
|
Tarsons Products
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Customer Wise Break-Up
|
Customer Wise Break-Up
|
-
|
-
|